Recent Quotes
My Watchlist
Indicators
Local Stocks
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

483.00 -15.73 (-3.15%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,260,057
Open 498.30
Bid (Size) 481.35 (1)
Ask (Size) 486.01 (1)
Prev. Close 498.73
Today's Range 480.79 - 498.63
52wk Range 341.93 - 510.63
Shares Outstanding 259,428,394
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Prediction: These 2 Stocks Will Beat the S&P 500 Through 2030
There's no need to change a winning formula. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Market Whales and Their Recent Bets on VRTX Options
Via Benzinga

Performance

YTD
+17.54%
+17.54%
1 Month
+1.07%
+1.07%
3 Month
-2.60%
-2.60%
6 Month
+20.77%
+20.77%
1 Year
+33.48%
+33.48%

More News

Read More
Vertex to Present Phase 3 Data Highlighting Suzetrigine’s Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists Annual Meeting
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (19 Ratings)
Via Benzinga
Here's How Much $1000 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth Today
Via Benzinga
What Analysts Are Saying About Vertex Pharmaceuticals Stock
Via Benzinga
If You Invested $100 In This Stock 15 Years Ago, You Would Have $1,200 Today
Via Benzinga
Demystifying Vertex Pharmaceuticals: Insights From 16 Analyst Reviews
Via Benzinga
Got $1,000? 2 Magnificent Growth Stocks to Buy and Hold Forever
Via The Motley Fool
3 No-Brainer Growth Stocks to Buy in October
Via The Motley Fool
Vertex to Announce Third Quarter 2024 Financial Results on November 4th
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
Via Benzinga
Looking Into Vertex Pharmaceuticals's Recent Short Interest
Via Benzinga
2 Biotech Stocks to Buy Hand Over Fist in October
Via The Motley Fool
Cathie Wood's Ark Invest Trades: Bets $14M On Amazon Shares — Dumps Robinhood Stock Worth $36M, Embraces Coinbase And Meta
Via Benzinga
S&P 500 Could Reach 6,300 In 12 Months, Says Goldman Sachs, Driven By 'Strong AI Demand' And 'Margin Expansion'
Via Benzinga
Topics Artificial Intelligence Stocks
Exposures Artificial Intelligence US Equities
Insider Trades: How To Find The Top Stocks
Via Talk Markets
3 Top Stocks That Could Still Rocket Higher in 2024
Via The Motley Fool
2 Superior Growth Stocks That Are Screaming Buys Right Now
Via The Motley Fool
Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit.
Via Investor's Business Daily
Vertex Highlights First Oral Presentation of Phase 3 Clinical Data of the Vanza Triple and New Data on Long-Term Impact of TRIKAFTA® at the North American Cystic Fibrosis Conference
From Vertex Pharmaceuticals Incorporated
Via Business Wire
The Best Biotech Stock to Invest $1,000 in Right Now
Via The Motley Fool
Bull Market and Beyond: 2 Stocks Just Waiting to Soar
Via The Motley Fool
Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030
Via The Motley Fool
3 Stocks to Buy and Hold Forever
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.